These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 21983154

  • 1. A randomized, double-blind noninferiority study of quadrivalent live attenuated influenza vaccine in adults.
    Block SL, Yi T, Sheldon E, Dubovsky F, Falloon J.
    Vaccine; 2011 Nov 21; 29(50):9391-7. PubMed ID: 21983154
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity and safety of a quadrivalent live attenuated influenza vaccine in children.
    Block SL, Falloon J, Hirschfield JA, Krilov LR, Dubovsky F, Yi T, Belshe RB.
    Pediatr Infect Dis J; 2012 Jul 21; 31(7):745-51. PubMed ID: 22466322
    [Abstract] [Full Text] [Related]

  • 3. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model.
    Rudenko L, Kiseleva I, Krutikova E, Stepanova E, Rekstin A, Donina S, Pisareva M, Grigorieva E, Kryshen K, Muzhikyan A, Makarova M, Sparrow EG, Torelli G, Kieny MP.
    PLoS One; 2018 Jul 21; 13(12):e0208028. PubMed ID: 30507951
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity of a quadrivalent Ann Arbor strain live attenuated influenza vaccine delivered using a blow-fill-seal device in adults: a randomized, active-controlled study*.
    Sheldon EA, Jeanfreau R, Sliman JA, Charenkavanich S, Rousculp MD, Dubovsky F, Mallory RM.
    Influenza Other Respir Viruses; 2013 Nov 21; 7(6):1142-50. PubMed ID: 23061976
    [Abstract] [Full Text] [Related]

  • 5. Quadrivalent Ann Arbor strain live-attenuated influenza vaccine.
    Toback SL, Levin MJ, Block SL, Belshe RB, Ambrose CS, Falloon J.
    Expert Rev Vaccines; 2012 Nov 21; 11(11):1293-303. PubMed ID: 23151111
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children.
    Bracco Neto H, Farhat CK, Tregnaghi MW, Madhi SA, Razmpour A, Palladino G, Small MG, Gruber WC, Forrest BD, D153-P504 LAIV Study Group.
    Pediatr Infect Dis J; 2009 May 21; 28(5):365-71. PubMed ID: 19395948
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.
    Vaccine; 2014 Mar 14; 32(13):1480-7. PubMed ID: 24486352
    [Abstract] [Full Text] [Related]

  • 8. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?
    Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA.
    Pediatrics; 2006 Sep 14; 118(3):e570-8. PubMed ID: 16950948
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity, safety and reactogenicity of a mammalian cell-culture-derived influenza vaccine in healthy children and adolescents three to seventeen years of age.
    Vesikari T, Block SL, Guerra F, Lattanzi M, Holmes S, Izu A, Gaitatzis N, Hilbert AK, Groth N.
    Pediatr Infect Dis J; 2012 May 14; 31(5):494-500. PubMed ID: 22301476
    [Abstract] [Full Text] [Related]

  • 10. Shedding of Ann Arbor strain live attenuated influenza vaccine virus in children 6-59 months of age.
    Mallory RM, Yi T, Ambrose CS.
    Vaccine; 2011 Jun 10; 29(26):4322-7. PubMed ID: 21513761
    [Abstract] [Full Text] [Related]

  • 11. Comparison of the efficacy and safety of live attenuated cold-adapted influenza vaccine, trivalent, with trivalent inactivated influenza virus vaccine in children and adolescents with asthma.
    Fleming DM, Crovari P, Wahn U, Klemola T, Schlesinger Y, Langussis A, Øymar K, Garcia ML, Krygier A, Costa H, Heininger U, Pregaldien JL, Cheng SM, Skinner J, Razmpour A, Saville M, Gruber WC, Forrest B, CAIV-T Asthma Study Group.
    Pediatr Infect Dis J; 2006 Oct 10; 25(10):860-9. PubMed ID: 17006278
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct 10; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 13. Safety and immunogenicity in man of a cell culture derived trivalent live attenuated seasonal influenza vaccine: a Phase I dose escalating study in healthy volunteers.
    Heldens J, Hulskotte E, Voeten T, Breedveld B, Verweij P, van Duijnhoven W, Rudenko L, van Damme P, van den Bosch H.
    Vaccine; 2014 Sep 03; 32(39):5118-24. PubMed ID: 24858566
    [Abstract] [Full Text] [Related]

  • 14. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials.
    Rhorer J, Ambrose CS, Dickinson S, Hamilton H, Oleka NA, Malinoski FJ, Wittes J.
    Vaccine; 2009 Feb 11; 27(7):1101-10. PubMed ID: 19095024
    [Abstract] [Full Text] [Related]

  • 15. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM.
    Pediatrics; 2006 Sep 11; 118(3):e579-85. PubMed ID: 16950949
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of live attenuated influenza vaccine in children against influenza B viruses by lineage and antigenic similarity.
    Belshe RB, Coelingh K, Ambrose CS, Woo JC, Wu X.
    Vaccine; 2010 Feb 25; 28(9):2149-56. PubMed ID: 20003926
    [Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer.
    Carr S, Allison KJ, Van De Velde LA, Zhang K, English EY, Iverson A, Daw NC, Howard SC, Navid F, Rodriguez-Galindo C, Yang J, Adderson EE, McCullers JA, Flynn PM.
    J Infect Dis; 2011 Nov 15; 204(10):1475-82. PubMed ID: 21949042
    [Abstract] [Full Text] [Related]

  • 18. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF, Zhang AJ, To KK, Chan JF, Li P, Wong TL, Zhang R, Chan TC, Chan BC, Wai HH, Chan LW, Fong HP, Hui RK, Kong KL, Leung AC, Ngan AH, Tsang LW, Yeung AP, Yiu GC, Yung W, Lau JY, Chen H, Chan KH, Yuen KY.
    Lancet Infect Dis; 2016 Feb 15; 16(2):209-18. PubMed ID: 26559482
    [Abstract] [Full Text] [Related]

  • 19. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections.
    Ashkenazi S, Vertruyen A, Arístegui J, Esposito S, McKeith DD, Klemola T, Biolek J, Kühr J, Bujnowski T, Desgrandchamps D, Cheng SM, Skinner J, Gruber WC, Forrest BD, CAIV-T Study Group.
    Pediatr Infect Dis J; 2006 Oct 15; 25(10):870-9. PubMed ID: 17006279
    [Abstract] [Full Text] [Related]

  • 20. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    BMC Infect Dis; 2013 Jul 24; 13():343. PubMed ID: 23883186
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.